Related Experiment Video
Updated: Apr 25, 2026
In Vitro Enzyme Measurement to Test Pharmacological Chaperone Responsiveness in Fabry and Pompe Disease
Published on: December 20, 2017
Diagnosis and management of Pompe disease
Insights
Pompe disease, a rare genetic neuromuscular disorder, requires early diagnosis and treatment to prevent fatal outcomes. This overview provides South African guidelines for timely diagnosis and multidisciplinary management.
Area of Science:
- Neuromuscular Disorders
- Rare Genetic Diseases
- Metabolic Myopathies
Background:
- Pompe disease (PD) is an autosomal-recessive neuromuscular disorder caused by acid alpha-glucosidase deficiency.
- Progressive glycogen accumulation leads to cellular damage and disease severity, influenced by onset age and organ involvement.
- PD presents across a spectrum from infantile to late-onset forms, each with specific clinical characteristics.
Purpose of the Study:
- To provide an overview of Pompe disease.
- To establish guidelines for diagnosis and management in South Africa.
- To emphasize the importance of early detection and multidisciplinary care.
Main Methods:
- Review of Pompe disease pathophysiology, classification, and diagnostic approaches.
- Outline of screening and confirmatory testing protocols.
- Recommendations for multidisciplinary team management.
Main Results:
- Pompe disease diagnosis requires specific screening and confirmatory tests to minimize false positives.
- Timely diagnosis is crucial for effective management and improved patient outcomes.
- A multidisciplinary team led by an experienced physician is optimal for patient care.
Conclusions:
- Early diagnosis and intervention are critical for managing Pompe disease.
- Standardized diagnostic and management guidelines are essential for South Africa.
- Multidisciplinary care improves outcomes for patients with this rare neuromuscular condition.
Abstract:
Pompe disease (PD) is an autosomal-recessively inherited neuromuscular disease that, if not diagnosed and treated early, can be fatal. It can present from early infancy into adulthood. Due to the lack of acid alpha-glucosidase, there is progressive intracellular accumulation of glycogen. The severity of the disease is determined by age of onset, organ involvement including the degree of severity of muscle involvement, as well as rate of progression. PD is classified into two groups: infantile and late-onset, each having two subgroups. The need for two tests performed by separate methods (screening and confirmatory) is outlined. It is imperative to try to reduce the time to diagnosis and to recognise the possibilities of false-positive results. A multidisciplinary team approach to treatment of affected patients is optimum with, as team leader, a physician who has experience in managing this rare disorder. In this article, we present a brief overview of the disease and provide guidelines for diagnosis and management of this condition in South Africa.
Related Concept Videos
01:30Cardiomyopathy II: Dilated Cardiomyopathy
01:29Cardiomyopathy V: Interprofessional Care
01:29Cardiomyopathy VI: Nursing Management
01:29Chronic Pancreatitis II: Collaborative Care
Assessment:
01:30Heart Failure V: Medical Management
01:26Methods of Documentation II: POMR